Interleukin-12 (IL12) is a powerful pro-inflammatory chemokine that enhances cytotoxic T cell-mediated cancer cell destruction. Il12-based cancer gene therapy can overcome the fatal side effects of IL12, but its clinical translational application is limited by the lack of systemic gene vectors that can effectively transfect tumors to produce enough IL12. Macrophages themselves secrete IL12, and tumor-associated macrophages (TAMs) are also a major component of tumors. Professor Shen Youqing of Zhejiang University, researchers Chen Chunying and Liu Ying of The National Center for Nanoscience and Nanotechnology have designed an IL12 gene delivery vector that can effectively transfect cancer cells and TAMs to become an IL12 production "factory", thus effectively activating anti-cancer immune responses and reshaping the tumor microenvironment.

Main points of this article:

(1) Research shows that this carrier can increase the Proportion of M1/M2 by more than four times. In all three animal models, intravenous administration of the vector significantly delayed tumor growth and doubled survival in mice, and the systemic toxicity was so low as to be negligible.

(2) This is also the first study to develop and construct a non-viral IL12 gene delivery system that can effectively utilize macrophages and tumor cells.

Nasha Qiu. et al. Tumor-Associated Macrophage and Tumor-Cell Dually Transfecting Polyplexes for Efficient Interleukin-12 Cancer Gene Therapy. Advanced Materials. 2020

DOI: 10.1002 / adma. 202006189

https://onlinelibrary.wiley.com/doi/10.1002/adma.202006189

Source: Theory of Oddities

This information is from the Internet for academic exchange only. If there is any infringement, please contact us to delete it immediately